Literature DB >> 15997485

Clinical manifestations, treatment and control of infections caused by Clostridium difficile.

E Bouza1, P Muñoz, R Alonso.   

Abstract

Clostridium difficile should be suspected in patients who present with nosocomial diarrhoea. It is more common in the elderly or in patients with a debilitating underlying condition who have received antimicrobial agents, and up to 20-25% of patients may experience a relapse. The reference method for diagnosis is the cell culture cytotoxin test which detects the presence of toxin B in a cellular culture of human fibroblasts, but recovering C. difficile in culture allows the performance of a ''second-look" cell culture assay that enhances the potential for diagnosis. Oral metronidazole (500 mg tid or 250 mg every 6 hrs) and oral vancomycin (125 mg every 6 hrs) administered for 1014 days have similar therapeutic efficacy, with response rates near 90-97%. C. difficile strains resistant to metronidazole and with intermediate resistance to vancomycin have been described. The administration of probiotics such as Saccharomyces boulardii, Lactobacillus sp. or brewer's yeast for prophylaxis of CDAD remains controversial.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997485     DOI: 10.1111/j.1469-0691.2005.01165.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  12 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

Review 3.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 4.  The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge.

Authors:  E R Dubberke; D B Haslam; C Lanzas; L D Bobo; C-A D Burnham; Y T Gröhn; P I Tarr
Journal:  Zoonoses Public Health       Date:  2010-09-24       Impact factor: 2.702

5.  Toxic megacolon associated Clostridium difficile colitis.

Authors:  Leena Sayedy; Darshan Kothari; Robert J Richards
Journal:  World J Gastrointest Endosc       Date:  2010-08-16

6.  Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial.

Authors:  John S Fordtran
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-01

7.  Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.

Authors:  Sandra Dial; J A Chris Delaney; Verena Schneider; Samy Suissa
Journal:  CMAJ       Date:  2006-09-26       Impact factor: 8.262

8.  Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile.

Authors:  Megan E Reller; Clara A Lema; Trish M Perl; Mian Cai; Tracy L Ross; Kathleen A Speck; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

9.  Molecular and structural discrimination of proline racemase and hydroxyproline-2-epimerase from nosocomial and bacterial pathogens.

Authors:  Maira Goytia; Nathalie Chamond; Alain Cosson; Nicolas Coatnoan; Daniel Hermant; Armand Berneman; Paola Minoprio
Journal:  PLoS One       Date:  2007-09-12       Impact factor: 3.240

10.  Clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile cultivated from stool samples of hospitalized patients.

Authors:  Stojanovic Predrag; Kocic Branislava; Stojanovic Miodrag; Miljkovic-Selimovic Biljana; Tasic Suzana; Miladinovic-Tasic Natasa; Babic Tatjana
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.